-
Guangzhou Nansha Biopharmaceutical Industrial Park to promote the development of biotechnology industry agglomeration
Time of Update: 2022-03-04
The reporter learned from the Nansha District Government of Guangzhou City on the 17th that the Hengli Biomedical Industrial Park project of Nansha Science and Technology Innovation Center has officially kicked off the construction .
-
24 companies "besieged" AZ's original research drug!
Time of Update: 2022-03-04
Coupled with the gradual advancement of consistency evaluation, large varieties of over-reviewed generic drugs are increasing day by day, which has also caused huge damage to original research drugs.
-
Domestic substitution accelerates the development of the orthopaedic implant device industry with a strong momentum
Time of Update: 2022-03-04
Based on the huge population base in China, the accelerated social aging process, and the rising demand for orthopedic medical care, the orthopedic implant device industry has developed rapidly in recent years, and there is still a broad market prospect and huge room for growth .
-
Qinghai: The price of drugs and medical consumables purchased in a centralized manner has dropped by more than 60% on average
Time of Update: 2022-03-04
Su Quanren, Secretary of the Party Group and Director of the Qinghai Provincial Health and Health Commission, introduced at the 2022 Qinghai Provincial Health and Health Work Conference on the 14th that the price of drugs and medical consumables purchased in a centralized manner in Qinghai Province has dropped by more than 60% on average, and the public's burden on medical drugs has been significantly reduced .
-
It is a major trend to expand 2,000 grass-roots health establishments in one place.
Time of Update: 2022-03-03
Expansion of 2,000 grassroots health service establishments Recently, according to Ningbo Evening News, the Ningbo Municipal Party Committee Editing Office in Zhejiang Province optimized the establishment resources, and the city increased the establishment of more than 2000 grassroots medical and health institutions .
-
21 varieties of China Resources Sanjiu have sold over 100 million yuan, and 1 new drug has attacked the market of 100 billion yuan
Time of Update: 2022-03-03
com, in 2021E China's urban physical pharmacy terminals, CR Sanjiu is expected to have a number of OTC varieties in the leading position, including Chinese patent medicine Ganmaoling granules, stomach medicine Chinese patent medicine Sanjiu Weitai granules, mineral supplements Calcium and zinc gluconate oral solution, etc.
-
The hospital is planned!
Time of Update: 2022-03-03
Each province (autonomous region, city) shall set up at least 1 provincial-level TCM regional medical center, and basically achieve full coverage of county-run TCM medical institutions in public hospitals with no more than 50 beds in each ward.
-
The Beijing-Tianjin-Hebei "3+N" Alliance Coronary Dilation Balloon Medical Consumables are here!
Time of Update: 2022-03-03
On February 15, Tianjin Pharmaceutical Purchasing Center released the "Beijing-Tianjin-Hebei "3+N" Alliance Coronary Dilation Balloon Medical Consumables Procurement and Use Work Plan with Volume Lin
-
Over $10 billion, the big variety meets the enemy Fu, Hausen... 78 ANDAs are won
Time of Update: 2022-03-03
The FDA Generic Drug Group (OGD) approved 736 ANDA projects throughout the year.
. It is worth noting that OGD approved 93 first generic drugs in 2021, of which there are 11 important first generic drugs designated by the FDA, including: linaclotide capsules, apremilast tablets, hydrocodone tartrate sustained-release tablets, Ibrutinib capsules, enzalutamide capsules, lenalidomide capsules, tofacitinib tablets, difluprednate ophthalmic lotion, varenicline tablets, linagliptin tablets, dasatinib tablets .
-
Purchasing with volume: Do not pursue the lowest price and firmly oppose running bidding
Time of Update: 2022-03-03
If the inter-provincial alliance is explored, but the competition pattern is not sufficient, the varieties are not many, and the total volume is not very large, on the basis of the successful exploration mechanism, the state will organize centralized procurement, so that the effect of this reform system can quickly benefit the whole country.
-
CSPC submits 4 types of generic marketing applications for rosuvastatin calcium tablets
Time of Update: 2022-03-03
When the rosuvastatin reported for production this time is successfully approved, it will soon become the company's fourth It is a lipid-lowering drug, and at the same time, it has increased the product line of CSPC in the field of blood lipid regulators .
-
23 pieces of decoction product specifications and formula granules have been negotiated and purchased, and the Sunshine Internet has accelerated the expansion!
Time of Update: 2022-03-03
Just after the Spring Festival of the Year of the Tiger, the Gansu Provincial Public Resource Trading Center released an important message on its official website: "Notice on the 2022 Negotiation and Purchasing of Traditional Chinese Medicine Pieces Sunshine Network Supplement" (hereinafter referred to as the "Notice") .
-
The IND application of Bozhiyan's new anti-tumor drug BCM323 oral solution was accepted by CDE!
Time of Update: 2022-03-03
me-better antitumor drug BCM323 oral solution adopts polymer micelle solubilization technology to improve the solubility and permeability of active substances in the gastrointestinal tract, and at the same time selects excipients reasonably to inhibit the efflux of P-glycoprotein .
-
Qilu, Yangzijiang and Kelun are leading the way!
Time of Update: 2022-03-03
On January 30, 2022, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry" was released. The data shows that during the "13th Five-Year Plan" period, 964 of 278 varieties pass
-
T-FIT becomes the thermal insulation solution of choice for China's COVID-19 vaccine production facilities
Time of Update: 2022-03-02
T-FIT modular foam insulation material has been installed and applied in the clean rooms of 9 major COVID-19 vaccine production facilities located across China .
Featuring ZOTEK high-performance foam produced by Zotefoams, T-FIT is the only true cross-linked PVDF polymer foam insulation product on the market .
-
9 injections were "processed" and 4 sales surged by more than 100%
Time of Update: 2022-02-21
A few days ago, the Hunan Provincial Medical Insurance Bureau issued a notice stating that the prices of the online listings within the same listing are quite different (especially in different perio
-
The 5th domestic Ruckus Pharma capecitabine tablet was approved for production and deemed to have been reviewed
Time of Update: 2022-02-21
On January 20, the official website of the State Food and Drug Administration showed that Nanjing Rucko Pharma’s Class 4 generic capecitabine tablets were approved for production and deemed to have been reviewed, making it the fifth domestically-produced company to be approved .
-
How to "block" Omicron as the risk of hidden transmission increases?
Time of Update: 2022-02-21
Continue to strengthen source control to prevent importation At present, Omicron has become the dominant epidemic strain in the world, spreading in more than 150 countries and regions, and the risk of being imported into China through people and things is gradually increasing .
-
Industry reshuffle continues!
Time of Update: 2022-02-21
Single-channel desalination and omni-channel testing In the past ten years, the sales channels of pharmaceutical companies have changed from the pure clinical hospital market to the “dual-track system” of hospital retailing, and then settled in the county-level grass-roots market after graded diagnosis and treatment, and then to today’s omni-channel open cooperation and integration of online Platform, hospital, retail, third terminal, covering multiple roles such as doctor, patient, payer, industry, retail and so on .
-
Good policy!
Time of Update: 2022-02-21
" In general, affected by objective conditions, traditional Chinese medicine Decoction pieces should not implement the "zero-markup rate" policy like Chinese and Western patent medicines and medical devices .
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
